| |
|
|
|
|
|
|
|||
|
Blood, Vol. 96 No. 1 (July 1), 2000:
pp. 58-62
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS
From the Service d'Anatomie Pathologique, Hôpital Paul
Brousse, and UPRES 1596, Université Paris-Sud, Villejuif; UMR
8603 CNRS/Université Paris V, Service d'Histo-Embryologie,
Hôpital, Service d'Anatomie Pathologique, Département de
Pédiatrie and INSERM U429, Hôpital Necker-Enfants Malades,
Paris; Département de Pédiatrie, Hôpital Debrousse,
Lyon, France; the Department of Immunology, Hospital de la Santa Creu i
Sant Paul, and the Immunology Unit, C. S. Vall d'Hebron, Barcelona,
Spain; Abteilung für Pathologie, Universität Ulm, Ulm,
Germany; and the Department of Pediatrics, University Hospital and
Clinics, Madison, WI.
Reticular dysgenesis is a rare inherited immunodeficiency
characterized by the lack of blood monocytes and neutrophils and low
lymphocyte counts, contrasting with normal red blood cell counts and
normal or decreased platelet counts. Whether dendritic cells or
macrophages, both of which derive primarily from blood monocytes, are
affected in this condition remains unknown. We studied 7 patients with
reticular dysgenesis. Macrophages were present in normal numbers in the
dermis and in the atrophic lymphoid tissues of these patients, proving
that at least some subsets of macrophages can differentiate despite
very low monocyte counts. By contrast, Langerhans cells, which are
CD1a-positive epidermal dendritic cells, were absent in all (n = 5)
patients before bone marrow transplantation. After bone marrow
transplantation, Langerhans cells were present (n = 2), suggesting
that the defect is not related to keratinocyte dysfunction. A split
chimeric reconstitution, characterized by the presence of autologous
blood monocytes able to differentiate in vitro into CD1a-positive
dendritic cells, was observed in a patient who underwent successful
engraftment. These results suggest that an intrinsic cell defect is
unlikely and that a bone marrow-derived factor may be defective in
reticular dysgenesis; it may be responsible for the Langerhans cell
defect but not involved in macrophage differentiation.
(Blood. 2000;96:58-62)
Dendritic cells (DC) have a crucial function in the
initiation of the antigen-specific immune response. They have the
unique properties of actively internalizing particles at their immature stage in most nonlymphoid tissues, of migrating toward the T cell areas
of secondary lymphoid organs, and of maturing and becoming able to activate naive T cells.1,2 Langerhans cells (LC) are immature DC of the malpighian and respiratory epithelium. They have
been particularly well studied because of their specific localization
within the epidermis, mucosa, and bronchi. They exhibit a
characteristic dendritic morphology, and they express markers such as
CD1a, major histocompatibility class II proteins, S100 proteins,3-5 and Birbeck granules. Human CD34+
hematopoietic progenitors6 and CD14+ blood
monocytes7 can differentiate in vitro into LC. In vivo, allogenic human LC are detectable as early as 2 weeks after allogenic bone marrow transplantation (BMT).8 The study of human or
animal primary immunodeficiencies should contribute to a better
understanding of in vivo LC differentiation. Although transforming
growth factor (TGF)- We have recently shown that some children with severe combined
immunodeficiency disease may lack LC.11 In the current
study, we investigated 7 patients with reticular dysgenesis (RD) before or after allogeneic BMT to determine whether macrophages and LC are
affected by this condition. RD is a rare inherited condition characterized by an absence of blood neutrophils and monocytes, low
lymphocyte counts, normal red blood cell counts, and normal or low
platelet counts.12 We report that a selective absence of LC
within the epidermis is a constant feature of this condition. Before
BMT, macrophages were detected in these patients, but LC were not.
After BMT, hematopoietic reconstitution was associated with the
presence of LC in the epidermis, even though 1 patient had a split
chimeric hematopoietic reconstitution with autologous blood monocytes.
Patients
Histology and immunohistochemistry
In vitro differentiation of CD14+ blood monocytes Patient and donor blood samples were transmitted by mail. Differentiation of DC from human blood monocytes was performed as described.7 Briefly, CD14+ monocytes were isolated from blood mononuclear cells by negative magnetic depletion using hapten-conjugated CD3, CD7, CD19, CD45RA, and anti-IgE antibodies and a magnetic cell separator, routinely resulting in 95% or greater purity of CD14+ cells. CD14+ monocytes were then cultured for 6 days in 250 ng/mL granulocyte macrophage-colony-stimulating factor (GM-CSF; Sandoz AG, Bale, Switzerland), 100 mg/mL IL-4 (Genzyme, Cambridge, MA), and 10 ng/mL TGF- 1 (R&D Systems, Minneapolis, MN).
Fluorescence in situ hybridization Dual-color fluorescence in situ hybridization (FISH) was performed with a biotinylated (peri)centromeric satellite DNA
probe specific for chromosome X (Oncor, Gaithersburg, MD) and a probe specific for chromosome Y heterochromatin. This chromosome Y-specific probe was obtained by polymerase chain reaction amplification of human
male genomic DNA with the following oligonucleotides: 5' TCC ACT
TTA TTC CAG GCC TGT CC 3' and 5' TTG AAT GGA ATG GGA ACG
AAT GG 3'. It was labeled with digoxigenin-11-dUTP by
nick-translation. The X-biotinylated and Y-digoxigenin-labeled probes
were revealed by Texas Red stain and FITC fluorochromes,
respectively. Slides were counter-stained with DAPI, mounted with an
anti-fading medium (Vector, Burlingame, CA), viewed using a Zeiss
Axiophot fluorescence microscope (Carl Weiss SA, Le Pecq,
France), and analyzed with the Applied Imaging system
(BioScience Centre, Newcastle upon Tyne, UK). On each
slide, the proportion of XY and XX cells was determined by counting
100 cells.
Detection of macrophages In contrast with monocyte defects, macrophages identified as
histiocytes expressing CD68 were detected in the dermis of 5 skin
samples from 4 children before BMT (Figure
1A). Some of these histiocytes were also
positive for HLA-DR. The amounts of macrophages within the dermis were
similar to those in control patients. Macrophages were also detected
within the sinuses of atrophic lymph nodes of 2 patients who did not
undergo BMT (Figure 1B,C). They were also present within the cortex of
lymph nodes, the red pulp of the spleen, the thymus, and several
nonlymphoid organs, including the pancreas and the parathyroid and
adrenal glands. In addition, macrophages were present within the dermis
of the 4 patients who underwent transplantation, whatever their
hematologic status.
Detection of Langerhans cells Identification of LC in skin sections was based on 3 criteria: localization within the epidermis, dendritic morphology, and expression of at least 1 of the 3 following markers: CD1a, HLA-DR, and S100 protein. Langerhans cells were undetectable in the 5 skin samples of the 4 patients before BMT (Figure 2A). However, LC of normal morphology and expressing CD1a, HLA-DR, and S100 protein (Figure 2B) were present in 2 of 4 samples from patients assessed after BMT (Table 1). The 2 patients who did not have LC had no evidence of bone marrow engraftment at the time of biopsy.
In vitro differentiation of dendritic cells In a patient who underwent successful BMT, evidence of a split chimeric reconstitution has been reported31 because his T cells originated from his sister, but his B cells and monocytes were of autologous origin. FISH detection of chromosomes X and Y was performed on the patient's blood cells. Most (71%) of the purified CD14+ blood monocytes from this patient were autologous (Figure 3), whereas most (80%) of his lymphocytes originated from the donor. These purified CD14+ monocytes were induced to differentiate in vitro into monocyte-derived DC in the presence of GM-CSF (100 ng/mL), IL-4 (10 ng/mL), and TGF- 1
(10 ng/mL). After a 6-day culture, most of the cells expressed very low
to negative CD14, and 60% were CD1a positive (Figure 4). Most (92%) of these DC generated in
vitro were XY (Figure 3). As controls, blood cells obtained from the
patient's sister and in vitro-generated CD1a-positive DC were all XX
(not shown). These results suggest that the impairment of LC
differentiation was an extrinsic cell defect. Unfortunately, though
FISH was performed on the skin sample of this patient, it was not
possible to distinguish unambiguously the putative Y
chromosome-positive LC from the Y chromosome-positive surrounding
autologous keratinocytes.
Reticular dysgenesis is an extremely rare primary immunodeficiency that accounts for 1% to 3% of severe combined immunodeficiencies.26,30,32 The myeloid lineage of patients with RD has a characteristic maturation arrest at the stage of promyelocyte.18 The mechanism responsible for the leukocyte maturation defect in RD is still unknown. Because rare mature blood leukocytes are detectable, the primary defect is supposed to interfere with the normal growth or survival of leukocytes rather than with the initiation of stem cell differentiation.21 Patients with RD can be cured by BMT, indicating that RD results from a primary defect of hematopoietic cells. The lack of blood leukocytes and LC may be caused by either a direct or an indirect (ie, intrinsic or extrinsic) mechanism. The split chimeric reconstitution of 1 patient after BMT argues for an extrinsic cell defect.
We warmly thank Drs A. Ferster and J. Pardo for providing histologic samples. We thank all the pathologists, immunologists, and pediatricians who gave us information concerning the availability of histologic samples from the published reports of reticular dysgenesis, particularly Drs R.H. Buckley, M.D. Cooper, D. Gitlin, R.J. Haas, R. Jaffe, H.P.W. Kozakewich, R.J. Lewinsky, R.C. McCoy, and S.V. Pizzo. We also thank M. Ortin-Serrano for expert technical assistance.
Submitted December 2, 1999; accepted February 19, 2000.
Supported by grants from the G.R.I.P.
Reprints: Jean-François Emile, Service d'Anatomie Pathologique, Hôpital Paul Brousse BP200, F-94804 Villejuif Cedex, France; e-mail: jean-francois.emile{at}pbr.ap-hop-paris.fr.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
1. Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol. 1991;9:271[Medline] [Order article via Infotrieve]. 2. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392:245[Medline] [Order article via Infotrieve]. 3. Romani N, Lenz A, Glassel H, et al. Cultured human Langerhans cells resemble lymphoid dendritic cells in phenotype and function. J Invest Dermatol. 1989;93:600[Medline] [Order article via Infotrieve]. 4. Teunissen MBM. Dynamic nature and function of epidermal Langerhans cells in vivo and in vitro: a review, with emphasis on human Langerhans cells. Histochem J. 1992;24:697[Medline] [Order article via Infotrieve]. 5. Emile JF, Fraitag S, Leborgne M, De Prost Y, Brousse N. Langerhans' cell histiocytosis cells are activated Langerhans' cells. J Pathol. 1994;174:71[Medline] [Order article via Infotrieve].
6.
Caux C, Dezutter-Dambuyant C, Schmitt D, Banchereau J.
GM-CSF and TNF-
7.
Geissmann F, Prost C, Monnet JP, Dy M, Brousse N, Hermine O.
Transforming growth factor 8. Emile JF, Haddad E, Fraitag S, Canioni D, Fischer A, Brousse N. Detection of donor-derived Langerhans cells in MHC class II immunodeficient patients after allogeneic bone marrow transplantation. Br J Haematol. 1997;98:480[Medline] [Order article via Infotrieve].
9.
Borkowski TA, Letterio JJ, Farr AG, Udey MC.
A role of endogenous transforming growth factor b1 in Langerhans cell biology: the skin of transforming growth factor b1 null mice is devoid of epidermal Langerhans cells.
J Exp Med.
1996;184:2417 10. Borkowski TA, Letterio JJ, Mackall CL, et al. A role for TGF beta 1 in Langerhans cell biology: further characterization of the epidermal Langerhans cell defect in TGF beta 1 null mice. J Clin Invest. 1997;100:575[Medline] [Order article via Infotrieve]. 11. Emile JF, Durandy A, Le Deist F, Fischer A, Brousse N. Epidermal Langerhans' cells in children with primary T-cell immune deficiencies. J Pathol. 1997;183:70[Medline] [Order article via Infotrieve]. 12. WHO scientific group. Primary immunodeficiency diseases. Clin Exp Immunol. 1995;99(suppl 1):2-15. 13. de Vaal OM, Seynhaeve V. Reticular dysgenesia. Lancet. 1959;ii:1123.
14.
Gitlin D, Vawter G, Craig JM.
Thymic alymphoplasia and congenital aleukocytosis.
Pediatrics.
1964;33:184 15. Alonso K, Dew JM, Starke WR. Thymic alymphoplasia and congenital aleukocytosis (reticular dysgenesia). Arch Pathol. 1972;94:179[Medline] [Order article via Infotrieve]. 16. Ownby DR, Pizzo S, Blackmon L, Gall SA, Buckley RH. Severe combined immunodeficiency with leukopenia (reticular dysgenesis) in siblings: immunologic and histopathologic findings. J Pediatr. 1976;89:382[Medline] [Order article via Infotrieve]. 17. Heymer B, Niethammer D, Haas R, Meister H, Haferkampf O. Pathologic findings in severe combined immunodeficiency and reticular dysgenesia. Virchows Arch. 1976;370:151. 18. Haas RJ, Niethammer D, Goldmann SF, Heit W, Bienzle U, Kleihauer E. Congenital immunodeficiency and agranulocytosis (reticular dysgenesia). Acta Paediatr Scand. 1977;66:279[Medline] [Order article via Infotrieve]. 19. Espanol T, Compte J, Alvarez C, Tallada N, Laverde N, Peguero G. Reticular dysgenesis: report of two brothers. Clin Exp Immunol. 1979;38:615[Medline] [Order article via Infotrieve]. 20. Levinsky RJ, Tiedeman K. Successful bone-marrow transplantation for reticular dysgenesis. Lancet 1983;i:671. 21. Roper M, Parmley RT, Crist WM, Kelly DR, Cooper MD. Severe combined leukopenia (reticular dysgenesis): immunologic and morphologic characterizations of leukocytes. Am J Dis Child. 1985;139:832. 22. Haas A, Wells J, Chin T, Stiehm ER. Successful treatment of reticular dysgenesis with haploidentical bone marrow transplantation [abstract]. Clin Res. 1986;34:127. 23. Chin TW, Plaeger-Marshall S, Haas A, Ank BJ, Stiehm ER. Lymphokine-activated killer cells in primary immunodeficiencies and acquired immunodeficiency syndrome. Clin Immunol Immunopathol. 1989;53:449[Medline] [Order article via Infotrieve]. 24. Heymer B, Friedrich W, Knobloch C, Goldmann SF. Reticular dysgenesis: primary disorder in differentiation of hematopoietic stem cells? Verh Dtsch Ges Path. 1960;74:106. 25. Bujan W, Ferster A, Azzi N, Devalck C, Leriche A, Sariban E. Use of recombinant human granulocyte colony stimulating factor in reticular dysgenesis. Br J Haematol. 1992;81:128[Medline] [Order article via Infotrieve]. 26. Stephan JL, Vlekova V, Le Deist F, et al. Severe combined immunodeficiency: a retrospective single-center study of clinical presentation and outcome in 117 patients. J Pediatr. 1993;123:564[Medline] [Order article via Infotrieve].
27.
Bujan W, Ferster A, Sariban E.
Effect of recombinant human granulocyte colony-stimulating factor in reticular dysgenesis.
Blood.
1993;82:1684 28. Azcona C, Alzina V, Barona P, Sierrasumaga L, Villa-Elizaga I. Use of recombinant human granulocyte-macrophage colony stimulating factor in an infant with reticular dysgenesis. Eur J Pediatr. 1994;153:164[Medline] [Order article via Infotrieve]. 29. De Santes KB, Lai SS, Cowan MJ. Haploidentical bone marrow transplantation for two patients with reticular dysgenesis. Bone Marrow Tranplant. 1996;17:1171. 30. Buckley RC, Schiff RI, Schiff SE, et al. Human severe combined immunodeficiency: genetic, phenotypic, and functional diversity in one hundred eight infants. J Pediatr. 1997;130:378[Medline] [Order article via Infotrieve]. 31. De La Calle-Martin O, Badell I, Garcia A, et al. B cells and monocytes are not developmentally affected in a case of reticular dysgenesis. Clin Exp Immunol. 1997;110:392[Medline] [Order article via Infotrieve].
32.
Fischer A, Landais P, Friedrich W, et al.
Bone marrow transplantation (BMT) in Europe for primary immunodeficiencies other than severe combined immunodeficiency: a report from the European Group for BMT and the European Group for Immunodeficiency.
Blood.
1994;83:1149 33. Friedrich W, Goldmann SF, Ebell W, et al. Severe combined immunodeficiency: treatment by bone marrow transplantation in 15 infants using HLA-haploidentical donors. Eur J Pediatr. 1985;144:125[Medline] [Order article via Infotrieve]. 34. Niehues T, Schwarz K, Schneider M, et al. Severe combined immunodeficiency (SCID) associated neutropenia: a lesson from monozygotic twins. Arch Dis Child. 1996;74:340[Abstract]. 35. Chapuis F, Rosenzwajg M, Yagello M, Ekman M, Biberfeld P, Gluckman JC. Differentiation of human dendritic cells from monocytes in vitro. Eur J Immunol. 1997;27:431[Medline] [Order article via Infotrieve]. 36. Massey HM, Flanagan AM. Human osteoclasts derive from CD14-positive monocytes. Br J Haematol. 1999;106:167[Medline] [Order article via Infotrieve].
37.
Sallusto F, Lanzavecchia A.
Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor 38. Witmer-Pack MD, Hughes DA, Schuler G, et al. Identification of macrophages and dendritic cells in the osteopetrotic (op/op) mouse. J Cell Sci. 1993;104:1021[Abstract]. 39. Shull M, Ormsby I, Kier A, et al. Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature. 1992;359:693[Medline] [Order article via Infotrieve].
40.
Scott EW, Simon MC, Anastasi J, Singh H.
Requirement of transcription factor PU.1 in the development of multiple hematopoietic lineages.
Science.
1994;265:1573 41. Scott EW, Fisher RC, Olson MC, Kehrli EW, Simon MC, Singh H. PU.1 functions in a cell-autonomous manner to control the differentiation of multipotential lymphoid-myeloid progenitors. Immunity. 1997;6:437[Medline] [Order article via Infotrieve].
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() |
A. Maheshwari and R. D. Christensen Neutropenia in the Neonatal Intensive Care Unit NeoReviews, October 1, 2004; 5(10): e431 - e443. [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||